Kotak Institutional Equities suggests that high US tariffs on pharmaceuticals are unlikely. They maintain an optimistic outlook on the sector, favouring companies like Sun Pharmaceuticals and Cipla, while noting India's significant role in supplying US generic drugs and biosimilars.